FY2024 EPS Estimates for Fennec Pharmaceuticals Inc. Reduced by Analyst (TSE:FRX)

Fennec Pharmaceuticals Inc. (TSE:FRXFree Report) – Investment analysts at Wedbush dropped their FY2024 earnings estimates for Fennec Pharmaceuticals in a research note issued to investors on Monday, March 18th. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company will post earnings of $0.50 per share for the year, down from their prior forecast of $0.64. The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is $0.43 per share. Wedbush also issued estimates for Fennec Pharmaceuticals’ FY2025 earnings at $0.86 EPS, FY2026 earnings at $3.70 EPS and FY2027 earnings at $4.29 EPS.

Fennec Pharmaceuticals Stock Performance

FRX stock opened at C$13.18 on Wednesday. The company has a debt-to-equity ratio of 881.09, a current ratio of 4.84 and a quick ratio of 10.17. The company has a fifty day moving average price of C$13.20 and a two-hundred day moving average price of C$12.04. Fennec Pharmaceuticals has a one year low of C$9.27 and a one year high of C$15.43. The stock has a market cap of C$352.04 million, a price-to-earnings ratio of -13.05 and a beta of 0.35.

Fennec Pharmaceuticals Company Profile

(Get Free Report)

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company. The company's product candidates include PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity hearing loss in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.

Further Reading

Earnings History and Estimates for Fennec Pharmaceuticals (TSE:FRX)

Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.